Inhibrx Biosciences (INBX) Operating Leases (2023 - 2025)
Historic Operating Leases for Inhibrx Biosciences (INBX) over the last 3 years, with Q3 2025 value amounting to $7.0 million.
- Inhibrx Biosciences' Operating Leases rose 28081.74% to $7.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.0 million, marking a year-over-year increase of 28081.74%. This contributed to the annual value of $8.0 million for FY2024, which is 15364.01% up from last year.
- Latest data reveals that Inhibrx Biosciences reported Operating Leases of $7.0 million as of Q3 2025, which was up 28081.74% from $7.5 million recorded in Q2 2025.
- Over the past 5 years, Inhibrx Biosciences' Operating Leases peaked at $8.0 million during Q4 2024, and registered a low of $1.8 million during Q3 2024.
- Moreover, its 3-year median value for Operating Leases was $7.0 million (2025), whereas its average is $5.4 million.
- Its Operating Leases has fluctuated over the past 5 years, first soared by 15364.01% in 2024, then skyrocketed by 28081.74% in 2025.
- Quarter analysis of 3 years shows Inhibrx Biosciences' Operating Leases stood at $3.2 million in 2023, then soared by 153.64% to $8.0 million in 2024, then fell by 13.17% to $7.0 million in 2025.
- Its last three reported values are $7.0 million in Q3 2025, $7.5 million for Q2 2025, and $7.9 million during Q1 2025.